MX2021002640A - Formas morficas de los inhibidores del factor d del complemento. - Google Patents

Formas morficas de los inhibidores del factor d del complemento.

Info

Publication number
MX2021002640A
MX2021002640A MX2021002640A MX2021002640A MX2021002640A MX 2021002640 A MX2021002640 A MX 2021002640A MX 2021002640 A MX2021002640 A MX 2021002640A MX 2021002640 A MX2021002640 A MX 2021002640A MX 2021002640 A MX2021002640 A MX 2021002640A
Authority
MX
Mexico
Prior art keywords
inhibitors
complement factor
morphic forms
compound
forms
Prior art date
Application number
MX2021002640A
Other languages
English (en)
Inventor
Avinash Phadke
Akihiro Hashimoto
Wei Ma
Lee M Katrincic
Original Assignee
Achillion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Achillion Pharmaceuticals Inc filed Critical Achillion Pharmaceuticals Inc
Publication of MX2021002640A publication Critical patent/MX2021002640A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Esta invención proporciona formas estables y altamente cristalinas del Compuesto 1 y Compuesto 2 de los inhibidores del factor D del Complemento para una eficacia farmacéutica terapéutica y una estabilidad de la forma de dosificación ventajosas.
MX2021002640A 2018-09-06 2019-09-06 Formas morficas de los inhibidores del factor d del complemento. MX2021002640A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862727954P 2018-09-06 2018-09-06
PCT/US2019/050073 WO2020051538A1 (en) 2018-09-06 2019-09-06 Morphic forms of complement factor d inhibitors

Publications (1)

Publication Number Publication Date
MX2021002640A true MX2021002640A (es) 2021-07-16

Family

ID=69723293

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021002640A MX2021002640A (es) 2018-09-06 2019-09-06 Formas morficas de los inhibidores del factor d del complemento.

Country Status (11)

Country Link
US (1) US11814363B2 (es)
EP (1) EP3847174A4 (es)
JP (1) JP2021536511A (es)
KR (1) KR20210057086A (es)
CN (1) CN112839945A (es)
AU (1) AU2019336238A1 (es)
BR (1) BR112021004263A2 (es)
CA (1) CA3111810A1 (es)
CO (1) CO2021004160A2 (es)
MX (1) MX2021002640A (es)
WO (1) WO2020051538A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3220626A1 (en) * 2021-05-28 2022-12-01 Aleksandar SKUBAN Use of complement factor d inhibitor for treatment of geographic atrophy secondary to age-related macular degeneration
KR20240069793A (ko) * 2021-09-30 2024-05-20 우한 크리에이터나 사이언스 앤드 테크놀로지 컴퍼니, 리미티드 보체 인자 d 억제제로서의 화합물, 이의 약학 조성물 및 용도
WO2023158772A1 (en) 2022-02-21 2023-08-24 Teva Pharmaceuticals International Gmbh Solid state forms of danicopan and process thereof
CN115872925B (zh) * 2023-02-22 2023-09-29 山东莱福科技发展有限公司 一种6-溴-3-甲基吡啶-2-胺的制备方法
WO2024191606A1 (en) * 2023-03-13 2024-09-19 Alexion Pharmaceuticals, Inc. Formulations of danicopan and methods of use thereof

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9206757D0 (en) 1992-03-27 1992-05-13 Ferring Bv Novel peptide receptor ligands
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5628984A (en) 1995-07-31 1997-05-13 University Of North Carolina At Chapel Hill Method of detecting lung disease
EP0894002A4 (en) 1996-03-13 2001-11-14 Univ Pennsylvania NEW PEPTIDES INHIBITING SUPPLEMENT ACTIVATION
AU7808198A (en) 1997-06-03 1998-12-21 Biocryst Pharmaceuticals, Inc. Novel compounds useful in the complement, coagulat and kallikrein pathways and method for their preparation
US6410561B1 (en) 1998-03-26 2002-06-25 Japan Tobacco Inc. Amide derivatives and nociceptin antagonists
HUP0103143A3 (en) 1998-09-09 2003-01-28 Metabasis Therapeutics Inc San Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase, process for their preparation and their use
KR20000047461A (ko) 1998-12-29 2000-07-25 성재갑 트롬빈 억제제
WO2001017980A1 (fr) 1999-09-03 2001-03-15 Ajinomoto Co., Inc. Nouveaux procedes de preparation de derives d'oxazepine
US7528165B2 (en) 2001-12-13 2009-05-05 National Health Research Institutes Indole compounds
ITMI20021527A1 (it) 2002-07-11 2004-01-12 Consiglio Nazionale Ricerche Anticorpi anti componente c5 del complemento e loro uso
AU2003255711B2 (en) 2002-07-16 2008-11-13 Amura Therapeutics Limited Biologically active compounds
EP2311479B1 (en) 2002-09-20 2014-07-23 The Trustees of The University of Pennsylvania Compstatin analogs with improved activity
FR2845382A1 (fr) 2002-10-02 2004-04-09 Sanofi Synthelabo Derives d'indazolecarboxamides, leur preparation et leur utilisation en therapeutique
EP1567487A4 (en) 2002-11-15 2005-11-16 Bristol Myers Squibb Co OPEN-CHAINED, PROLYL-FROSTED MODULATORS OF ANDROGEN RECEPTOR FUNCTION
AU2003902946A0 (en) 2003-06-12 2003-06-26 Fujisawa Pharmaceutical Co., Ltd. Dpp-iv inhibitor
US7482376B2 (en) 2003-07-03 2009-01-27 3-Dimensional Pharmaceuticals, Inc. Conjugated complement cascade inhibitors
ES2432112T3 (es) 2004-02-10 2013-11-29 The Regents Of The University Of Colorado, A Body Corporate Inhibición del factor B, de la vía alternativa del complemento y métodos relacionados
PT1727811E (pt) 2004-03-24 2015-02-09 Shire Orphan Therapies Gmbh Novos compostos para inibição de angiogénese e a sua respectiva utilização
SI1755616T1 (sl) 2004-04-08 2014-04-30 Eye Co Pty Ltd. Zdravljenje eksudativne retinopatije z mineralkortikoidi
US7417063B2 (en) 2004-04-13 2008-08-26 Bristol-Myers Squibb Company Bicyclic heterocycles useful as serine protease inhibitors
WO2006012373A2 (en) 2004-07-20 2006-02-02 Critical Therapeutics, Inc. Combination therapies of hmgb and complement inhibitors against inflammation
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
RU2474586C2 (ru) 2005-11-28 2013-02-10 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Эффективные аналоги компстатина
BRPI0619733A2 (pt) 2005-12-12 2011-10-11 Genelabs Tech Inc compostos antivirais de n-(anel aromático de 6 membros)-amido
WO2007106585A1 (en) 2006-03-15 2007-09-20 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
EP2108642A1 (en) 2006-10-17 2009-10-14 Kyowa Hakko Kirin Co., Ltd. Jak inhibitor
DK2119703T3 (da) 2007-01-15 2013-01-14 Santen Pharmaceutical Co Ltd Nyt indolderivat med inhiberende virkning på I-B-kinase.
PL2148691T3 (pl) 2007-02-05 2015-12-31 Apellis Pharmaceuticals Inc Analogi kompstatyny do stosowania w leczeniu stanów zapalnych układu oddechowego
KR101657637B1 (ko) 2007-12-11 2016-09-19 글락소 그룹 리미티드 항원 결합성 단백질
CA2710644C (en) 2007-12-24 2016-03-29 Tibotec Pharmaceuticals Macrocyclic indoles as hepatitis c virus inhibitors
WO2009091826A2 (en) 2008-01-14 2009-07-23 The Board Of Regents Of The University Of Texas System Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car)
MX2011001371A (es) 2008-08-05 2011-06-16 Novartis Ag Composiciones y metodos para anticuerpos que se dirigen a la proteina de complementos c5.
CN104887389B (zh) 2009-01-29 2017-06-23 弗赛特影像4股份有限公司 后段给药
HUE035378T2 (en) 2009-05-01 2018-05-02 Univ Pennsylvania Compstatin with peptide framework and C-terminal modifications
WO2010135717A2 (en) 2009-05-21 2010-11-25 Potentia Pharmaceuticals, Inc. Complement assays and uses thereof
JP5758298B2 (ja) 2009-10-16 2015-08-05 持田製薬株式会社 非アルコール性脂肪肝炎関連マーカー
EP2496259B1 (en) 2009-11-05 2017-02-22 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria
PL2719699T3 (pl) 2009-12-31 2016-01-29 Hutchison Medipharma Ltd Pewne triazolopirazyny, ich kompozycje i sposoby ich stosowania
AU2011239966B2 (en) 2010-04-16 2014-05-08 Ac Immune S.A. Novel compounds for the treatment of diseases associated with amyloid or amyloid-like proteins
WO2011163394A2 (en) 2010-06-22 2011-12-29 Apellis Pharmaceuticals, Inc. Compstatin analogs for treatment of neuropathic pain
US20130324482A1 (en) 2010-07-09 2013-12-05 Apellis Pharmaceuticals, Inc. Compstatin analogs for treatment of rhinosinusitis and nasal polyposis
KR20140027090A (ko) 2011-01-04 2014-03-06 노파르티스 아게 연령-관련 황반 변성 (amd)의 치료에 유용한 인돌 화합물 또는 그의 유사체
RU2653439C9 (ru) 2011-05-11 2018-10-16 Апеллис Фармасьютикалс, Инк. Клеточно-реактивные аналоги компстатина, аналоги компстатина длительного действия или аналоги компстатина нацеленного действия и их применение
JP6198721B2 (ja) 2011-05-27 2017-09-20 アキリオン ファーマシューティカルズ，インコーポレーテッド Ｈｃｖ感染症を治療するのに有用な置換されたアリファン、シクロファン、ヘテラファン、ヘテロファン、ヘテロ−ヘテラファンおよびメタロセン
CN103929961A (zh) 2011-06-20 2014-07-16 美国阿尔茨海默病研究所公司 化合物及其治疗应用
AU2012272706B2 (en) 2011-06-22 2017-07-06 Apellis Pharmaceuticals, Inc. Methods of treating chronic disorders with complement inhibitors
US20130035392A1 (en) 2011-08-01 2013-02-07 Mcgeer Patrick L Selective inhibition of the membrane attack complex of complement and C3 convertase by low molecular weight components of the aurin tricarboxylic acid synthetic complex
DK2753636T3 (da) 2011-09-07 2020-02-03 Univ Pennsylvania Compstatinanaloger med forbedret farmakokinetiske egenskaber
NZ742005A (en) 2012-05-03 2019-04-26 Kala Pharmaceuticals Inc Pharmaceutical nanoparticles showing improved mucosal transport
US9056874B2 (en) 2012-05-04 2015-06-16 Novartis Ag Complement pathway modulators and uses thereof
EP3058951A1 (en) 2012-06-18 2016-08-24 Omeros Corporation Compositions and methods of inhibiting masp-1 and/or masp-2 and/or masp-3 for the treatment of various diseases and disorders
US9579360B2 (en) 2012-06-20 2017-02-28 The Trustees Of The University Of Pennsylvania Methods of treating or preventing periodontitis and diseases associated with periodontitis
EP2864322B1 (en) 2012-06-20 2016-04-27 Novartis AG Complement pathway modulators and uses thereof
WO2014002052A1 (en) 2012-06-28 2014-01-03 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
WO2014002054A1 (en) 2012-06-28 2014-01-03 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
CA2876993A1 (en) 2012-06-28 2014-01-03 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
US9815819B2 (en) 2012-06-28 2017-11-14 Novartis Ag Complement pathway modulators and uses thereof
EP2867224B1 (en) 2012-06-28 2017-07-26 Novartis AG Pyrrolidine derivatives and their use as complement pathway modulators
US9487483B2 (en) 2012-06-28 2016-11-08 Novartis Ag Complement pathway modulators and uses thereof
WO2014002059A1 (en) 2012-06-29 2014-01-03 Novartis Ag CRYSTALLINE FORMS OF 1-(2-((1R,3S,5R)-3-(((R)-1-(3-chloro-2-fluorophenyl)ethyl)carbamoyl)-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-1Hpyrazolo[3,4-c]pyridine-3-carboxamide
WO2014005150A1 (en) 2012-06-29 2014-01-03 Novartis Ag Crystalline forms of l-(2-((lr,3s,5r)-3-( (2 -fluoro-3 - (trifluoromethoxy) phenyl) carbamoyl) - 2 -azabicycl o [3.1.0] hexan- 2 -yl) - 2 -oxoethyl) - 5 -methyl - 1h - pyrazolo [3, 4 -c] pyridine - 3 - carboxami de and salts thereof
US9550755B2 (en) 2012-07-12 2017-01-24 Novartis Ag Complement pathway modulators and uses thereof
WO2014037480A1 (en) 2012-09-10 2014-03-13 F. Hoffmann-La Roche Ag 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
US20160194359A1 (en) 2012-11-15 2016-07-07 Apellis Pharmaceuticals, Inc. Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
EP3660033B9 (en) 2012-11-15 2022-06-22 Apellis Pharmaceuticals, Inc. Long-acting compstatin analogs and related compositions and methods
JP6563815B2 (ja) 2013-01-23 2019-08-21 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント 天然抗体に由来する構築物を標的化すること及びその使用
CN105229003B (zh) 2013-03-14 2017-03-15 诺华股份有限公司 作为补体因子b抑制剂用于治疗眼科疾病的2‑(1h‑吲哚‑4‑基甲基)‑3h‑咪唑并[4,5‑b]吡啶‑6‑甲腈衍生物
WO2014152391A1 (en) 2013-03-15 2014-09-25 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
JP2016169161A (ja) 2013-07-19 2016-09-23 大日本住友製薬株式会社 新規イミダゾピリジン化合物
EP3290922A1 (en) 2013-08-07 2018-03-07 Alexion Pharmaceuticals, Inc. Atypical hemolytic uremic syndrome (ahus) biomarker proteins
WO2015054569A1 (en) 2013-10-10 2015-04-16 Viropharma Holdings Limited Methods of inhibiting the alternative pathway of complement immune system activation and compositions used therein
JP2017508788A (ja) 2014-02-25 2017-03-30 アキリオン ファーマシューティカルズ，インコーポレーテッド 補体媒介障害の治療のためのエーテル化合物
WO2017035413A2 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Carbamate, ester, and ketone compounds for treatment of immune and inflammatory disorders
WO2017035352A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Carbamate, ester, and ketone compounds for treatment of medical disorders
AR105808A1 (es) 2015-08-26 2017-11-08 Achillion Pharmaceuticals Inc Compuestos de amida para el tratamiento de trastornos médicos
WO2017035357A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Phosphonate compounds for treatment of medical disorders
WO2017035409A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
WO2017035355A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Ether compounds for treatment of medical disorders
WO2017035362A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Use of complement pathway inhibitor compounds to mitigate adoptive t-cell therapy associated adverse immune responses
WO2017035348A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Alkyne compounds for treatment of medical disorders
ES2908479T3 (es) 2015-08-26 2022-04-29 Achillion Pharmaceuticals Inc Compuestos para el tratamiento de trastornos inmunitarios e inflamatorios
WO2017035418A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Disubstituted compounds for treatment of immune and inflammatory disorders
AR105809A1 (es) 2015-08-26 2017-11-08 Achillion Pharmaceuticals Inc Compuestos para el tratamiento de trastornos médicos
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
WO2017035415A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Alkyne compounds for treatment of immune and inflammatory disorders
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
WO2017035417A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Phosphonate compounds for treatment of immune and inflammatory disorders
WO2017035351A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of medical disorders
WO2017035361A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Disubstituted compounds for the treatment of medical disorders
WO2017035411A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Ether compounds for treatment of immune and inflammatory disorders
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
EP3386504A4 (en) 2015-12-11 2019-05-22 Lifesci Pharmaceuticals, Inc. THERAPEUTIC INHIBITOR COMPOUNDS
CA3010735C (en) 2016-01-14 2023-06-13 Chemocentryx, Inc. Use of n-benzoyl-2-phenyl-3-phenylcarbamoyl-piperidin derivative for treating complement 3 glomerulopathy
AU2017210042B2 (en) 2016-01-20 2021-01-21 396419 B.C. Ltd. Compositions and methods for inhibiting Factor D
TWI747873B (zh) 2016-02-01 2021-12-01 美商百歐克斯製藥公司 苯并吡唑化合物及其類似物
EP3448389B1 (en) 2016-06-27 2021-09-29 Achillion Pharmaceuticals, Inc. Quinazoline and indole compounds to treat medical disorders
JOP20170154B1 (ar) 2016-08-01 2023-03-28 Omeros Corp تركيبات وطرق لتثبيط masp-3 لعلاج أمراض واضطرابات مختلفة
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
WO2018160892A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for treatment of medical disorders
IL294069B2 (en) 2017-03-01 2023-11-01 Achillion Pharmaceuticals Inc Aryl, heteroaryl and heterocyclic pharmaceutical compounds for the treatment of medical disorders
CN111163767A (zh) 2017-08-02 2020-05-15 艾其林医药公司 治疗阵发性睡眠性血红蛋白尿症的治疗方案
AU2018345625A1 (en) 2017-10-04 2020-04-16 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-C5 antibodies for treatment of patients with Membranoproliferative glomerulonephritis
US11759472B2 (en) 2017-11-21 2023-09-19 Cs Pharmaceuticals Limited Compositions and methods of use for treating aberrant inflammation in peri-ocular secretory glands or at the ocular surface
US20190359645A1 (en) 2018-05-03 2019-11-28 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide
WO2020069024A1 (en) 2018-09-25 2020-04-02 Achillion Pharmaceuticals, Inc. Morphic forms of complement factor d inhibitors
WO2020109343A1 (en) 2018-11-29 2020-06-04 F. Hoffmann-La Roche Ag Combination therapy for treatment of macular degeneration
CN113195472A (zh) 2018-12-17 2021-07-30 艾其林医药公司 用于治疗补体介导的病症的靶向给药
MX2022001268A (es) 2019-07-31 2022-02-22 Biocryst Pharm Inc Regimenes de dosificacion para inhibidores orales del factor d del complemento.

Also Published As

Publication number Publication date
EP3847174A4 (en) 2022-06-15
WO2020051538A1 (en) 2020-03-12
CN112839945A (zh) 2021-05-25
KR20210057086A (ko) 2021-05-20
CA3111810A1 (en) 2020-03-12
BR112021004263A2 (pt) 2021-05-25
EP3847174A1 (en) 2021-07-14
US11814363B2 (en) 2023-11-14
CO2021004160A2 (es) 2021-04-30
JP2021536511A (ja) 2021-12-27
US20230094124A1 (en) 2023-03-30
AU2019336238A1 (en) 2021-04-08

Similar Documents

Publication Publication Date Title
MX2021002640A (es) Formas morficas de los inhibidores del factor d del complemento.
JOP20200122B1 (ar) مركبات مفيدة لتثبيط cdk7
MX2021003425A (es) Formas morficas de los inhibidores del factor d del complemento.
MX2023004593A (es) Inhibidores de tirosina cinasa 2 (tyk2) y usos de los mismos.
MX2023008031A (es) Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos.
PH12020551717A1 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
PH12020552154A1 (en) Compounds
EA202090413A1 (ru) Пиразоло- и триазолобициклические соединения в качестве ингибиторов jak киназы
EA202190681A1 (ru) Амиды диметиламиноазетидина в качестве jak ингибиторов
MX2023002507A (es) Inhibidores de cd73.
EA202090052A1 (ru) Содержащие имидазол ингибиторы alk2 киназы
EA202190686A1 (ru) 5-7-членные гетероциклические амиды в качестве ингибиторов jak
MX2020010942A (es) Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales.
CL2020001020A1 (es) Derivados de bencimidazol y sus usos.
MX2020001531A (es) Nuevos compuestos hetorociclicos como inhibidores de cdk8/19.
MX2022005256A (es) Inhibidores de cd73.
EA202191192A1 (ru) Кристаллические соли ингибитора плазменного калликреина
MX2020011756A (es) Compuesto farmaceutico, sales del mismo, formulaciones del mismo y metodos para hacer y usar el mismo.
EA201891319A1 (ru) Соединения алкилдигидрохинолинсульфонамида
EA202090424A1 (ru) Бициклические ингибиторы гистондеацетилазы
MX2022013964A (es) Inhibidores de glucosilceramidasa no lisosomal y los usos de los mismos.
CR20220600A (es) Inhibidores de glucosilceramidasa no lisosomal y los usos de los mismos
EA202190452A1 (ru) Ингибиторы cdk8/19
EA201792676A1 (ru) Ингибиторы jak1
PH12019502662A1 (en) Compounds